Cargando…
Immunogenicity and safety among laboratory workers vaccinated with Bexsero® vaccine
Neisseria meningitidis serogroup B is the most prevalent cause of invasive meningococcal disease in Europe and members of laboratories working on meningococci are at risk due to frequent handling. Recommendation for anti-meningococcal vaccination among these workers has been recently updated upon th...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5360120/ https://www.ncbi.nlm.nih.gov/pubmed/27808594 http://dx.doi.org/10.1080/21645515.2016.1241358 |
_version_ | 1782516537549127680 |
---|---|
author | Hong, Eva Terrade, Aude Taha, Muhamed-Kheir |
author_facet | Hong, Eva Terrade, Aude Taha, Muhamed-Kheir |
author_sort | Hong, Eva |
collection | PubMed |
description | Neisseria meningitidis serogroup B is the most prevalent cause of invasive meningococcal disease in Europe and members of laboratories working on meningococci are at risk due to frequent handling. Recommendation for anti-meningococcal vaccination among these workers has been recently updated upon the licensure in Europe of Bexsero® vaccine. We tested the immunogenicity and safety of this vaccine among adults laboratory staff using the recommended schedule of 2 doses at 5 weeks interval. The vaccine was well tolerated in spite of frequent local side effects and all participants reported at least one side effect after each dose. Immunogenicity was evaluated 6 weeks and one year after the second dose. All participants showed increase in their bactericidal titers against the components of the vaccine 6 weeks after the second dose, however titers declined significantly one year later. |
format | Online Article Text |
id | pubmed-5360120 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Taylor & Francis |
record_format | MEDLINE/PubMed |
spelling | pubmed-53601202017-03-29 Immunogenicity and safety among laboratory workers vaccinated with Bexsero® vaccine Hong, Eva Terrade, Aude Taha, Muhamed-Kheir Hum Vaccin Immunother Short Report Neisseria meningitidis serogroup B is the most prevalent cause of invasive meningococcal disease in Europe and members of laboratories working on meningococci are at risk due to frequent handling. Recommendation for anti-meningococcal vaccination among these workers has been recently updated upon the licensure in Europe of Bexsero® vaccine. We tested the immunogenicity and safety of this vaccine among adults laboratory staff using the recommended schedule of 2 doses at 5 weeks interval. The vaccine was well tolerated in spite of frequent local side effects and all participants reported at least one side effect after each dose. Immunogenicity was evaluated 6 weeks and one year after the second dose. All participants showed increase in their bactericidal titers against the components of the vaccine 6 weeks after the second dose, however titers declined significantly one year later. Taylor & Francis 2016-11-03 /pmc/articles/PMC5360120/ /pubmed/27808594 http://dx.doi.org/10.1080/21645515.2016.1241358 Text en © The Author(s). Published with license by Taylor & Francis http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The moral rights of the named author(s) have been asserted. |
spellingShingle | Short Report Hong, Eva Terrade, Aude Taha, Muhamed-Kheir Immunogenicity and safety among laboratory workers vaccinated with Bexsero® vaccine |
title | Immunogenicity and safety among laboratory workers vaccinated with Bexsero® vaccine |
title_full | Immunogenicity and safety among laboratory workers vaccinated with Bexsero® vaccine |
title_fullStr | Immunogenicity and safety among laboratory workers vaccinated with Bexsero® vaccine |
title_full_unstemmed | Immunogenicity and safety among laboratory workers vaccinated with Bexsero® vaccine |
title_short | Immunogenicity and safety among laboratory workers vaccinated with Bexsero® vaccine |
title_sort | immunogenicity and safety among laboratory workers vaccinated with bexsero® vaccine |
topic | Short Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5360120/ https://www.ncbi.nlm.nih.gov/pubmed/27808594 http://dx.doi.org/10.1080/21645515.2016.1241358 |
work_keys_str_mv | AT hongeva immunogenicityandsafetyamonglaboratoryworkersvaccinatedwithbexserovaccine AT terradeaude immunogenicityandsafetyamonglaboratoryworkersvaccinatedwithbexserovaccine AT tahamuhamedkheir immunogenicityandsafetyamonglaboratoryworkersvaccinatedwithbexserovaccine |